awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q48142028-60F2D46A-7466-4AFF-B92A-86490617DDF3
Q48142028-60F2D46A-7466-4AFF-B92A-86490617DDF3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48142028-60F2D46A-7466-4AFF-B92A-86490617DDF3
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin.
P2860
Q48142028-60F2D46A-7466-4AFF-B92A-86490617DDF3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48142028-60F2D46A-7466-4AFF-B92A-86490617DDF3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
59ea07476ede1de0047782aeea4af5d1eb2d22d6
P2860
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.